Metabolism, Excretion and Bioavailability of Hydroxysafflor Yellow A after Oral Administration of Its Lipid-Based Formulation and Aqueous Solution in Rats

Chinese Journal of Natural Medicines

Volumn 8, Issue 3, 2010, Pages 233-240

  LI, Jiang Ran ^a   SUN, Min Jie ^a   Ping, Qi Neng ^a   CHEN, Xi Jing ^a   QI, Jian Ping ^a   HAN, De En ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bile; Excretion; Hydroxysafflor Yellow A; Lipid based formulation; Metabolite

Indexed keywords

GLUTATHIONE; HERBACEOUS AGENT; HYDROXYSAFFLOR YELLOW A; LIPID; SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77952579759     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.3724/SP.J.1009.2010.00223     Document Type: Article

References (15)

1. Wang T., Fu F., Han B., et al. Mechanism of hydroxysafflor yellow A on protecting ischemic myocardium [J]. J Mol Cell Cardiol 40 (2006) 957
2. Vaidyanathan J.B., and Walle T. Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes [J]. Drug Metab Dispos 30 8 (2002) 897-903
3. Tulayakul P., Dong K.S., and Li J.Y. The effect of feeding piglets with the diet containing green tea extracts or coumarin on in vitro metabolism of aflatoxin B1 by their tissues [J]. Toxicon 50 3 (2007) 339-348
4. Chen Y., Xie S., Chen S., et al. Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9 [J]. Biochem Pharmacol 76 3 (2005) 416-425
5. Gradolatto A., Canyvenc-Lavier M.C., and Basly J.P. Metabolism of apigenin by liver phase I and phase II enzymes and by isolated perfused rat liver [J]. Drug Metab Dispos 32 1 (2004) 58-65
6. Manach C., and Donovan J.L. Pharmacokinetics and metabolism of dietary flavonoids in humans [J]. Free Rad Res 38 8 (2004) 771-785
7. Ljusberg-Wahren H., Nielsen F.S., Brogård M., et al. Enzymatic characterization of lipid-based drug delivery systems [J]. Int J Pharm 298 2 (2005) 328-332
8. Fernandez S., Jannin V., Rodier J.D., et al. Comparative study on digestive lipase activities on the self-emulsifying excipient Labrasol, medium chain glycerides and PEG esters [J]. Biochim Biophys Acta 1771 5 (2007) 633-640
9. Wang S., Sun M., and Ping Q. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats [J]. Int J Pharm 358 1-2 (2008) 198-204
10. Chu D., Liu W., Huang Z., et al. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from Safflower, in rats and dogs [J]. Planta Med 72 5 (2006) 418-423
11. Zhang H., Guo J., Huang L., et al. Pharmacokinetics of hydroxysafflor yellow A in rats [J]. J China Pharm Univ 37 5 (2006) 456-460
12. Wang S., Sun M., and Ping Q. Preparation and physicochemical properties study of hydroxysafflor yellow A-phospholipid complex [J]. Pharm Clin Res 16 1 (2008) 01-05
13. Fröhlich A.K., Girreser U., and Clement B. Metabolism of benzamidoxime (N-hydroxyamidine) in human hepatocytes and role of UDP-glucuronosyltransferases [J]. Xenobiotica 35 1 (2005) 17-25
14. Khoo S.M., Shackleford D.M., Porter C.J., et al. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs[J]. Pharm Res 20 9 (2003) 1460-1465
15. Legen I., Salobir M., and Kerc J. Comparison of different intestinal epithelia as models for absorption enhancement studies [J]. Int J Pharm 291 1-2 (2005) 183-188